Further clinical studies are required to analyze the potential benefit of extending the indication for HER2-targeted therapies, for example, for brain-metastasized patients with initially triple-negative BC PTs, either via dual blockade by trastuzumab/pertuzumab or via agents such as T-DM1, which was shown to be superior in the EMILIA study [48, 49], or possibly lapatinib, a dual tyrosine kinase inhibitor that interferes with both the epidermal growth factor receptor (EGFR) and HER2 signaling pathways. Here, EGFR is linked to breast cancer.